Trinity Biotech (TRIB) Operating Leases (2019 - 2025)

Trinity Biotech (TRIB) has reported Operating Leases for 7 consecutive years, with $10.6 million the latest figure, recorded in Q2 2025.

• Quarterly Operating Leases rose 3.48% year-over-year to $10.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $10.6 million (up 3.48% YoY) and the FY2024 annual result came in at $10.5 million, down 3.63% from the prior year.
• Operating Leases grew to $10.6 million in Q2 2025 per TRIB's latest filing, from $10.5 million in the prior quarter.
• Over the last five years, Operating Leases for TRIB reached as high as $13.9 million in Q4 2021 and fell as low as $9.7 million in Q3 2024.
• A 5-year average of $11.3 million and a median of $10.9 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases fell 16.42% — and 2025, when it grew 3.48%.
• Year by year, Operating Leases stood at $13.9 million in 2021, then retreated by 11.53% to $12.3 million in 2022, then retreated by 11.37% to $10.9 million in 2023, then declined by 3.63% to $10.5 million in 2024, then increased by 0.73% to $10.6 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $10.6 million, $10.5 million, and $9.7 million for Q2 2025, Q4 2024, and Q3 2024 respectively.